/Investor DB

Frazier Healthcare Partners — 2020 Investments

5 investments dated 2020 · listed companies and verified rows first · show all

Amunix Pharmaceuticalsamunix.comSeries A · Mar 2020 · $73M

Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.

BiotechSouth San Francisco, US

Trisha Millican(Director)James Topper(Director)Otello Stampacchia(Director)David Hirsch(Director)Volker Schellenberger(Executive Officer)James Brush(Director)

Co-investorsBain Capital Life SciencesFrazier Life SciencesLongitude CapitalViking GlobalBlackRockCasdin Capital+6 more

Aspen Neuroscienceaspenneuroscience.comin𝕏Apr 2020 · $70M

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)

Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32+10 more

Imagoimagobio.comin𝕏Nov 2020 · $80Macquired by Merck

A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments.

BiotechHealthtech

Co-investorsFrazier Life SciencesHighlight CapitalMRL Ventures FundXeraya CapitalAmgen VenturesBlackRock+5 more

Lassen Therapeuticslassentherapeutics.cominJun 2020 · $31M

Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.

Biotech

David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in

Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersFrazier Life SciencesLongitude CapitalLongwood Fund+2 more

MBX Biosciencesmbxbio.comin𝕏Series A · Jul 2020 · $35M

MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases.

BiotechHealthtechCarmel, US

Richard DiMarchi(Founder)Peter Kent Hawryluk(Executive Officer, Director)Timothy Knickerbocker(Executive Officer, Director)inSteve Hoerter(Chairman & Chief Executive Officer)inSalomon Azoulay(Chief Medical Officer)inKaren Basbaum(Chief Business Officer)in

Co-investorsFrazier Life SciencesNorwest Venture PartnersIU VenturesNew Enterprise Associates (NEA)OrbiMedWellington Management

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.